Eamon N. Dreisbach , 2025-05-04 21:12:00
Key takeaways:
- Data from patients with wet AMD who received nine injections of faricimab were analyzed.
- Study results suggested rapid improvements in anatomy in both previously treated and treatment-naïve patients.
SALT LAKE CITY — Faricimab demonstrated “rapid improvements” in anatomic features across previously treated and treatment-naïve patients, according to 3-year study results.
“The TRUCKEE study is a real-world study investigating the efficacy and safety of faricimab in neovascular age-related macular degeneration,” Hannah Khan, MPH, told Healio at the Association for Research in Vision and Ophthalmology meeting. “We are now at 3 years, and we’re seeing maintenance in vision and fluid status.”
Khan and colleagues conducted a retrospective chart review of patients participating in the TRUCKEE study.
“We are increasing our data set in terms of how many patients are involved in this study, and we’re seeing long-term follow-up,” she said. “Right now we’re looking at nine injections of faricimab with pretty significant maintenance of fluid and vision.”
Patients who received nine injections of faricimab were stratified into three groups: all-switch (n = 436), aflibercept-switch (n = 269) and treatment-naïve (n = 61). Results showed that the benefits from faricimab increased with continuous treatment. The rates of idiopathic orbital inflammation and endophthalmitis were low, and only one case of nonocclusive vasculitis was reported. Additionally, a large number of patients showed complete resolution of intraretinal or subretinal fluid.
“We’re also seeing an extension of treatment intervals,” Khan said. “As we move on through the study and we increase patients’ injections, we are able to extend their intervals between injections.”
Sources/Disclosures
Collapse
Khan H, et al. The TRUCKEE study: Real-world efficacy and safety of faricimab in neovascular AMD – 3 year results. Presented at: Association for Research in Vision and Ophthalmology meeting; May 4-8, 2025; Salt Lake City.
Disclosures:
Khan reports having been employed by Genentech.
